Data published in the journal Obesity shows that slightly more than 50% of patients stop using semaglutide or tirzepatide for obesity treatment within a year
A high proportion of patients achieved significant weight loss, underscoring the drugs potential to improve metabolic outcomes, enhance quality of life, and reduce cardiometabolic risks
Shes beyond kind and listens to my ultimate goal for IV/injections
These medications are meant to be used long-term to sustain the benefits
Research in rodents indicates that apart from the activation of MMP2, the peptide might also activate fibroblasts, which produce and maintain MMP2 and other components of the extracellular matrix, such as collagen and elastin
None of these are a reason to stop the other treatment without clinical advice your prescriber will weigh the trade-offs and may suggest alternatives where they exist